参考文献

［1］Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction［J］. N Engl J Med, 2006, 355(3): 251-259.

［2］Bouabdallaoui N, Claggett B, Zile MR, et al. Growth differentiation factor-15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: The PARADIGM-HF trial［J］. Eur J Heart Fail, 2018, 20(12): 1701-1709.(https://www.daowen.com)

（田德丽　李建美）